menu
    • menu
    [{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clevudine","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tolimidone","moa":"Tyrosine-protein kinase Lyn","graph1":"Endocrinology","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Melior Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tolimidone","moa":"Tyrosine-protein kinase Lyn","graph1":"Endocrinology","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Bukwang Pharmaceutical Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Bukwang Pharmaceutical Co., Ltd

    Menu

    Bukwang Pharmaceutical Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus

                            Details : Levovir (clevudine) was found to be effective on virus isolated from the specimens of Korean Coronavirus Infectious Disease-19 (COVID-19) patients, similar to calletra used for the treatment of COVID-19 in vitro.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2020

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolimidone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Melior Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

                            Details : MLR-1023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2017

                            Lead Product(s) : Tolimidone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Melior Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolimidone

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Melior Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adult Subjects With Uncontrolled Type 2 Diabetes

                            Details : MLR-1023 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2014

                            Lead Product(s) : Tolimidone

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Melior Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Elevar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-Escalation and Safety Trial of YN968D1

                            Details : Apatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 22, 2011

                            Lead Product(s) : Apatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Elevar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth